It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. Wha ...

A few months ago, I published my investment thesis on Novo Nordisk ( NVO ), which I highly recommend reviewing before continuing with this article, as it provides my general outlook on the sector and I am an investor who relies on the fundamental aspects of companies. I enjoy being the owner of the world's best businesses with strong long-term projections. To achieve this, I conduct thorough research on the companies I invest in, placing significant importance on the sector, competitive advantages, and mana ...

Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 750.42 per share and has been calculated as the three-day volume weighted average market price from 6 November ...

Novo Nordisk A/S (NVO) reported third-quarter 2024 earnings of 90 cents per American Depositary Receipt (ADR), which marginally missed the Zacks Consensus Estimate of 91 cents. The company had reported earnings of 73 cents per ADR in the year-ago quarter.Revenues of $10.5 billion increased 21% in Danish kroner (DKK) and 23% at constant exchange rate (CER) in the reported quarter. However, total revenues also missed the Zacks Consensus Estimate of $10.7 billion. The year-over-year increase in revenues was dr ...

Novo Nordisk A/S (NVO) Q3 2024 Earnings Conference Call November 6, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President and Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President and Head of North America Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President ...

Key TakeawaysAfter rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.Sales rose 21% from the same time last year, but analysts had expected them to rise a bit higher.The Danish drugmaker also narrowed its full-year projections for revenue and operating profit. After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell a ...

Key TakeawaysNovo Nordisk's U.S.-listed shares rose Wednesday morning as third-quarter profits beat estimates and sales of Ozempic and Wegovy continued to grow.Sales rose 21% from the same time last year, but analysts had expected them to rise a bit higher.The Danish drugmaker also narrowed its full-year projections for revenue and operating profit. Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including po ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.The Danish pharmaceutical giant said that its net profit in the third quarter hit 27.3 billion Danish kroner ($3.92 billion), above an LSEG aggregate estimate of 26.95 billion Danish kroner.EBIT — earnings before tax and income — came to 33.8 billion Danish kroner, also just above the LSEG forecast of 33.51 billion Danish kroner.The company also narrowed its sales growt ...

Financial Performance - Operating profit increased by 21% in Danish kroner and by 22% at constant exchange rates (CER) to DKK 91.6 billion [1] - Net sales grew by 23% in Danish kroner (24% at CER) to DKK 204,720 million [2] - Net profit increased by 18% to DKK 72,758 million [2] - Diluted earnings per share grew by 19% to DKK 16.29 [2] Regional Sales Performance - North America Operations sales increased by 31% in Danish kroner (31% at CER) [1] - International Operations sales grew by 13% in Danish kroner (15% at CER) [1] Therapeutic Area Performance - Diabetes and Obesity care sales increased by 25% in Danish kroner (26% at CER) to DKK 191.8 billion [1] - GLP-1 diabetes sales grew by 25% in Danish kroner (26% at CER) [1] - Obesity care sales surged by 44% in Danish kroner (44% at CER) to DKK 43.7 billion [1] - Rare disease sales increased by 3% in both Danish kroner and at CER [1] R&D Progress - Completed phase 2a trial with monlunabant in obesity, with phase 2b trial planned for 2025 [1] - Oral semaglutide demonstrated statistically significant reduction in major adverse cardiovascular events in the SOUL trial [1] - Semaglutide 2.4 mg showed superior improvement in liver fibrosis and MASH resolution in the ESSENCE trial [1] 2024 Outlook - Sales growth expected to be 23-27% at CER [1] - Operating profit growth projected at 21-27% at CER [1] - Growth in Danish kroner expected to be 1 percentage point lower than CER for sales and 2 percentage points lower for operating profit [1] Company Overview - Global healthcare company founded in 1923, headquartered in Denmark [4] - Focuses on defeating serious chronic diseases, with heritage in diabetes [4] - Employs approximately 72,000 people in 80 countries [4] - Markets products in around 170 countries [4] - Listed on Nasdaq Copenhagen (Novo-B) and New York Stock Exchange (NVO) [4] Leadership Commentary - CEO highlighted strong performance driven by GLP-1-based diabetes and obesity treatments [3] - Emphasized positive R&D read-outs across semaglutide portfolio [3]

Key TakeawaysDanish pharmaceutical giant Novo Nordisk is set to report earnings for the third quarter of 2024 on Wednesday morning.Sales of its popular weight-loss drugs Ozempic and Wegovy will be Novo investors' focus.Analysts are generaly bullish on the stock, with five "hold" ratings and six "buy" ratings and an average price target about 28% above recent levels. Novo Nordisk (NVO), maker of popular weight-loss drugs Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall ...